使用Malat1小干扰RNA或雄激素受体剪接变异体7降解增强剂ASC-J9®抑制恩扎卢胺耐药性前列腺癌进展的临床前研究
该临床前研究建立恩扎卢胺耐药(EnzR)前列腺癌细胞系,发现长链非编码RNA Malat1是恩扎卢胺诱导雄激素受体剪接变异体7(AR-v7)产生所必需。靶向Malat1/AR-v7轴(Malat1小干扰RNA或AR-v7降解增强剂ASC-J9®)在细胞系和小鼠模型中抑制EnzR前列腺癌进展。局限性包括同一批患者治疗前后样本量小。
要点
- Malat1是恩扎卢胺诱导VCaP和EnzR-C4-2细胞产生AR-v7所必需。
- 在EnzR细胞系及部分接受恩扎卢胺治疗的患者中观察到AR-v7和Malat1表达增加。
- 靶向Malat1/AR-v7轴在细胞系和小鼠模型中抑制恩扎卢胺耐药前列腺癌进展。
核心结论
- 通过Malat1小干扰RNA或AR-v7降解增强剂ASC-J9®靶向Malat1/AR-v7轴,在EnzR前列腺癌细胞系和小鼠模型中抑制EnzR前列腺癌进展。
研究设计与样本
- 临床前研究:建立恩扎卢胺耐药(EnzR)前列腺癌细胞系,检测Malat1在赋予恩扎卢胺耐药中的功能,并检测Malat1小干扰RNA和AR-v7降解增强剂ASC-J9®的体内效应。
主要发现
- Malat1是恩扎卢胺诱导VCaP和EnzR-C4-2细胞产生AR-v7所必需。
- 在建立的EnzR前列腺癌细胞系及部分接受恩扎卢胺治疗的前列腺癌患者中观察到AR-v7和Malat1表达增加。
- 靶向Malat1/AR-v7轴改变了前列腺癌对恩扎卢胺雄激素剥夺治疗的耐药性。
临床怎么用
- 作者在患者摘要中指出,对于Malat1/雄激素受体剪接变异体7轴表达较高的前列腺癌患者,雄激素剥夺治疗-恩扎卢胺治疗可能不是最佳选择。
- 作者在患者摘要中指出,未来可能开发使用Malat1小干扰RNA或ASC-J9®的新疗法以更好地抑制恩扎卢胺耐药前列腺癌。
局限性
- 本研究局限性包括同一批人类患者接受恩扎卢胺治疗前后的样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While androgen-deprivation-therapy with the recently developed antiandrogen enzalutamide (Enz) shows promising therapeutic benefits in men with metastatic castration-resistant prostate cancer (PCa), many patients develop resistance to Enz, which may involve the induction of the androgen receptor (AR) splicing variant 7 (AR-v7). OBJECTIVE: Our aim is to identify the mechanisms responsible for AR-v7 production and to develop novel preclinical approaches to suppress the Enz-resistant (EnzR) PCa. DESIGN, SETTING, AND PARTICIPANTS: We established EnzR-PCa cell lines and examined the long noncoding RNA Malat1 (Malat1) function in conferring Enz resistance. We also examined the in vivo effects of Malat1 short interfering RNA and the AR-v7 degradation enhancer, ASC-J9®. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Enz resistance and expression of Malat1 and AR-v7. All statistical comparisons were analyzed with a t-test or one way analysis of variance followed by t-test. RESULTS AND LIMITATIONS: We demonstrated that Malat1 is indispensable for Enz-induced AR-v7 production in VCaP and EnzR-C4-2 cells. We observed increased AR-v7 and Malat1 expression in our established EnzR-PCa cell lines and in some PCa patients who received Enz treatment. Targeting the Malat1/AR-v7 axis resulted in altering the PCa resistance to androgen deprivation therapy with Enz. The limitation of this study includes the small sample size from the same human patients before and after receiving Enz treatment. CONCLUSIONS: Targeting the Malat1/AR-v7 axis via Malat1-short interfering RNA or AR-v7 degradation enhancer ASC-J9® in EnzR-PCa cell lines and mouse models suppressed EnzR-PCa progression. PATIENT SUMMARY: Androgen deprivation therapy-enzalutamide treatment may not be the best choice for prostate cancer patients who have higher expression of the Malat1/androgen receptor splicing variant 7 axis, and new therapies using Malat1-short interfering RNA or ASC-J9® may be developed in the future to better suppress enzalutamide-resistant prostate cancer.
引用
- Wang R, Sun Y, Li L, et al. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9® to Suppress Enzalutamide-resistant Prostate Cancer Progression. Eur Urol. 2017. PMID: 28528814. doi:10.1016/j.eururo.2017.04.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。